Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

INAB READ THE FULL INAB RESEARCH REPORT Following the announcement of its new γδ T cell engager platform INB-600, IN8bio, Inc ...

Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.

appeared necessary and sufficient for Treg development 2 electrified investigators by providing the first specific marker identifying these enigmatic cells. T cells capable of inhibiting immune ...

A T-cell therapy developed by Orca Bio, a private biotech company, significantly reduced the risk of a debilitating immune ...

Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...